WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 5 fonti

Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage.

Raccontata daforbes.comcnbc.combbc.comupi.comaljazeera.com

Confronto fonti

5 prospettive sulla stessa storia
AI · summaries
cnbc.comStai leggendo7 mesi fa

Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage.

originale
bbc.com7 mesi fa

Trump unveils deals to lower US weight-loss drug prices

US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.

Leggi questa versione → originale
aljazeera.com7 mesi fa

Weight-loss drug makers announce pricing agreement with Trump

The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.

Leggi questa versione → originale
upi.com7 mesi fa

Trump announces deal to lower prices for obesity drugs - UPI.com

Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.

Leggi questa versione → originale
forbes.com7 mesi fa

Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs

The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 6 novembre 2025·forbes.com

    Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs

    The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.

  2. giovedì 6 novembre 2025·cnbc.com

    Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

    The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high U.S. drug costs.

  3. giovedì 6 novembre 2025·bbc.com

    Trump unveils deals to lower US weight-loss drug prices

    US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.

  4. giovedì 6 novembre 2025·cnbc.com

    Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

    The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage.

  5. giovedì 6 novembre 2025·upi.com

    Trump announces deal to lower prices for obesity drugs - UPI.com

    Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.

  6. giovedì 6 novembre 2025·aljazeera.com

    Weight-loss drug makers announce pricing agreement with Trump

    The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.

  7. venerdì 7 novembre 2025·cnbc.com

    Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk

    Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.